Boltwood Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.73M Buy
6,880
+5
+0.1% +$1.08K 0.4% 57
2026
Q1
$1.5M Sell
6,875
-5
-0.1% -$1.11K 0.38% 64
2025
Q4
$1.57M Sell
6,880
-16
-0.2% -$3.65K 0.41% 60
2025
Q3
$1.6M Sell
6,896
-45
-0.6% -$9.16K 0.43% 56
2025
Q2
$1.29M Sell
6,941
-59
-0.8% -$11K 0.37% 66
2025
Q1
$1.47M Sell
7,000
-65
-0.9% -$12.6K 0.45% 58
2024
Q4
$1.26M Sell
7,065
-100
-1% -$18.4K 0.38% 63
2024
Q3
$1.41M Sell
7,165
-45
-0.6% -$8.4K 0.42% 62
2024
Q2
$1.24M Buy
7,210
+10
+0.1% +$1.66K 0.39% 63
2024
Q1
$1.31M Sell
7,200
-274
-4% -$47.2K 0.41% 66
2023
Q4
$1.16M Sell
7,474
-50
-0.7% -$7.29K 0.38% 68
2023
Q3
$1.12M Sell
7,524
-120
-2% -$17.6K 0.42% 63
2023
Q2
$1.03M Sell
7,644
-120
-2% -$17.6K 0.37% 69
2023
Q1
$1.24M Buy
7,764
+250
+3% +$38.2K 0.46% 52
2022
Q4
$1.21M Sell
7,514
-172
-2% -$26.4K 0.49% 52
2022
Q3
$1.03M Sell
7,686
-91
-1% -$13.1K 0.47% 59
2022
Q2
$1.19M Sell
7,777
-52
-0.7% -$7.95K 0.52% 58
2022
Q1
$1.27M Sell
7,829
-251
-3% -$36.5K 0.49% 63
2021
Q4
$1.09M Sell
8,080
-58
-0.7% -$6.85K 0.4% 79
2021
Q3
$878K Sell
8,138
-150
-2% -$17.1K 0.35% 85
2021
Q2
$934K Sell
8,288
-176
-2% -$19.8K 0.39% 82
2021
Q1
$916K Sell
8,464
-142
-2% -$15.2K 0.41% 77
2020
Q4
$922K Hold
8,606
0.45% 72
2020
Q3
$754K Sell
8,606
-43
-0.5% -$4.05K 0.42% 79
2020
Q2
$849K Sell
8,649
-55
-0.6% -$4.84K 0.51% 66
2020
Q1
$663K Sell
8,704
-520
-6% -$44.3K 0.47% 74
2019
Q4
$817K Hold
9,224
0.46% 73
2019
Q3
$698K Hold
9,224
0.44% 78
2019
Q2
$671K Hold
9,224
0.43% 78
2019
Q1
$743K Hold
9,224
0.48% 72
2018
Q4
$850K Hold
9,224
0.58% 57
2018
Q3
$872K Hold
9,224
0.52% 61
2018
Q2
$854K Sell
9,224
-200
-2% -$19.5K 0.56% 60
2018
Q1
$891K Sell
9,424
-1,478
-14% -$162K 0.61% 54
2017
Q4
$1.05M Hold
10,902
0.64% 53
2017
Q3
$968K Sell
10,902
-600
-5% -$45.7K 0.63% 55
2017
Q2
$834K Sell
11,502
-350
-3% -$23.5K 0.56% 62
2017
Q1
$772K Hold
11,852
0.54% 65
2016
Q4
$742K Hold
11,852
0.57% 61
2016
Q3
$747K Sell
11,852
-100
-0.8% -$6.47K 0.6% 57
2016
Q2
$740K Hold
11,952
0.62% 58
2016
Q1
$683K Hold
11,952
0.6% 58
2015
Q4
$708K Buy
11,952
+400
+3% +$23K 0.65% 52
2015
Q3
$629K Buy
11,552
+148
+1% +$9.63K 0.67% 49
2015
Q2
$766K Sell
11,404
-116
-1% -$7.57K 0.75% 46
2015
Q1
$674K Hold
11,520
0.2% 68
2014
Q4
$754K Hold
11,520
0.22% 64
2014
Q3
$665K Sell
11,520
-116
-1% -$6.44K 0.2% 70
2014
Q2
$657K Buy
11,636
+2,770
+31% +$145K 0.19% 68
2014
Q1
$456K Sell
8,866
-300
-3% -$15.2K 0.14% 72
2013
Q4
$484K Sell
9,166
-134
-1% -$6.59K 0.16% 71
2013
Q3
$416K Sell
9,300
-650
-7% -$28.8K 0.15% 70
2013
Q2
$411K Buy
+9,950
New +$435K 0.17% 70

Other funds holding ABBV

Boltwood Capital Management's ABBV Position: Q2 2026 in Review

Boltwood Capital Management increased its AbbVie (ABBV) stake by 0.07% in Q2 2026, buying an estimated $1.08K and bringing the position to 6,880 shares worth $1.73M. The position accounts for 0.4% of the portfolio, ranked #57.

Boltwood Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Boltwood Capital Management held 6,880 shares of AbbVie worth $1.73M as of Q2 2026.
  • Boltwood Capital Management bought 5 AbbVie shares in Q2 2026, an estimated $1.08K.
  • AbbVie made up 0.4% of Boltwood Capital Management's portfolio in Q2 2026, its #57 holding.
  • Boltwood Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Boltwood Capital Management's 13F filing for Q2 2026, filed 6 Jul 2026.